Johnson & Johnson Advances the Next Generation of Solid Tumor Therapies With New Data at ESMO 2026
October 24, 2026
October 24, 2026
RARITAN, New Jersey, Oct. 24 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026
- First readout following acquisition of the RIPTAC(TM) platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer
- New first-line head and neck cancer d . . .
* * *
Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026
- First readout following acquisition of the RIPTAC(TM) platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer
- New first-line head and neck cancer d . . .